(Reuters) - It also said it would assume $10 million in net JDS liabilities.
Noven said it sees an annual sales opportunity from JDS products -- which include drugs for bipolar disorder, depression and panic disorder -- of more than $500 million starting in 2012, assuming development and regulatory approval on current schedules.
Read more at Reuters.com Mergers News
Noven said it sees an annual sales opportunity from JDS products -- which include drugs for bipolar disorder, depression and panic disorder -- of more than $500 million starting in 2012, assuming development and regulatory approval on current schedules.
Read more at Reuters.com Mergers News
No comments:
Post a Comment